Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Purdue Univ. PTPN22 compound L-32: sourced facts only. name: "Finally, L-32 is superior to L-1 in reducing MC38 tumor growth in vivo by promoting robust antitumor immunity, thus offering a promising lead molecule for the development of novel anticancer agents targeting PTPN22." [PMID:42388138]; target: "Finally, L-32 is superior to L-1 in reducing MC38 tumor growth in vivo by promoting robust antitumor immunity, thus offering a promising lead molecule for the development of novel anticancer agents targeting PTPN22." [PMID:42388138]; developer: "Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907, United States." [PMID:42388138]; stage: "Finally, L-32 is superior to L-1 in reducing MC38 tumor growth in vivo by promoting robust antitumor immunity, thus offering a promising lead molecule for the development of novel anticancer agents targeting PTPN22." [PMID:42388138]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Purdue Univ. PTPN22 compound L-32.